The FDA has been working with bioprinting as of lately. With a new leader set to take place, what will this mean?

Scott Gottlien, a physician and policy expert at the American Enterprise Institute is said to likely be nominated by President Donald Trump as the next commissioner at the FDA.   Gottlieb edged out Jim O’Neill, a libertarian venture capitalist backed by billionaire investor Peter Thiel, for the nod.

As Gottlieb prepares for the his Senate confirmation hearings, there’s likely to be lots of interest in his public thoughts on healthcare.  Let’s see what this means for the world of bioprinting. Read below to see this Forbes article with Scott Gottlien.